Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (all population), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus nab-paclitaxel (ACnp)carboplatine plus nab-paclitaxel (CnP)first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer and no ALK or EGFR mutations who have not previously received chemotherapy483 / 240some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.400 / 400some concern
inconclusive
  • suggested 24 % decrease in deaths (OS)
  • suggested 39 % decrease in progression or deaths (PFS)
atezolizumab plus carboplatin plus paclitaxel
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus paclitaxel (ACP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.402 / 400some concern
inconclusive
    no statistically significant result